Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

RemeGen Licenses RC148 Bispecific to AbbVie for Up to $5.6 Billion in Milestones

Fineline Cube Jan 13, 2026
Company Deals

Boehringer Ingelheim & Jazz Launch Phase I HER2 Breast Cancer Combo with Zongertinib & Zanidatamab

Fineline Cube Jan 13, 2026
Company Deals Digital

Thermo Fisher Scientific Partners with NVIDIA in $280 Million AI Deal to Automate Laboratory Operations

Fineline Cube Jan 13, 2026
Company Deals

SciNeuro Pharmaceuticals Licenses Alzheimer’s BBB Antibody Platform to Novartis in $1.5 Billion Deal

Fineline Cube Jan 13, 2026
Company Deals

CARsgen Therapeutics Enters Phase I Collaboration with Dispatch Bio for CT053 CAR‑T in Solid Tumors

Fineline Cube Jan 13, 2026
Policy / Regulatory

China’s NHSA Launches Pre‑Communication Pilot for Reference Drugs, Targeting Category 1 Innovative Drugs

Fineline Cube Jan 13, 2026
Company Drug

Alphamab Oncology Submits Envafolimab for First‑Line Biliary Tract Cancer (BTC) as World’s First Subcutaneous PD‑L1

Fineline Cube Jan 12, 2026
Company Drug

Pfizer’s BRAFTOVI Trio Achieves 64 % Response Rate in BREAKWATER Cohort 3 for BRAF V600E Metastatic Colorectal Cancer

Fineline Cube Jan 12, 2026
Company Deals

Pinetree Therapeutics Strikes EGFR Degrader Deal with AstraZeneca Worth Over USD 500 Million

Fineline Cube Jul 25, 2024

Pinetree Therapeutics Inc., a Massachusetts-based biotechnology company, has announced the signing of an exclusive option...

Company Deals

Novartis Partners with Dren Bio to Develop Next-Generation Cancer Therapies

Fineline Cube Jul 25, 2024

Novartis (NYSE: NVS), a leading Swiss pharmaceutical company, has entered into a strategic collaboration with...

Company Drug

Pfizer’s Hemophilia A Gene Therapy Shows Promise in Phase III AFFINE Study

Fineline Cube Jul 25, 2024

Pfizer Inc. (NYSE: PFE), a US pharmaceutical giant, has announced positive topline results from the...

Company Drug

Novo Nordisk’s Wegovy Approved in the UK to Reduce Cardiovascular Risks in Overweight Adults

Fineline Cube Jul 24, 2024

Novo Nordisk (NYSE: NVO)’s anti-obesity drug Wegovy (semaglutide) has received a new indication approval in...

Company Drug

IASO Biotherapeutics’ CAR-T Therapy Fucaso Receives FDA IND Approval for Multiple Sclerosis

Fineline Cube Jul 24, 2024

China-based IASO Biotherapeutics has announced that it has received Investigational New Drug (IND) approval from...

Company Drug

ST Phi Therapeutics’ Universal Cell Therapy for Solid Tumors Gets Green Light for Clinical Trial in China

Fineline Cube Jul 24, 2024

ST Phi Therapeutics, a Hangzhou-based cell therapy specialist, has secured tacit approval from China’s National...

Company

Shanghai Rightongene Biotechnology Co., Ltd Executives Under Investigation by Chinese Authorities

Fineline Cube Jul 24, 2024

Shanghai Rightongene Biotechnology Co., Ltd (SHA: 688217), a Chinese biopharmaceutical company, has announced that key...

Company Medical Device

Hangzhou Jianjia Medical’s Arthbot Surgical Robot Receives NMPA Approval for Orthopedic Procedures

Fineline Cube Jul 24, 2024

Hangzhou Jianjia Medical Technology Co., Ltd has received marketing approval from China’s National Medical Products...

Company Drug

Innorna’s Herpes Zoster mRNA Vaccine IN001 Receives Clinical Trial Approval in China

Fineline Cube Jul 24, 2024

Shenzhen-based Innorna Co., Ltd has announced that it has received approval from the National Medical...

Company

BeiGene Launches Flagship US Facility in New Jersey to Expand Oncology R&D and Manufacturing

Fineline Cube Jul 24, 2024

BeiGene (NASDAQ: BGNE; HKG: 6160; SHA: 688235), a global biotechnology company, has announced the inauguration...

Company Drug

Bayer’s BAY 3375968 Receives NMPA Approval for Clinical Trial in Advanced Solid Tumors

Fineline Cube Jul 24, 2024

Bayer AG (ETR: BAYN), a multinational pharmaceutical giant based in Germany, has received clinical trial...

Company Drug

Chipscreen’s HDAC Inhibitor Chidamide to be Tested in Combination Therapy for CRC by NMPA

Fineline Cube Jul 24, 2024

Shenzhen Chipscreen Biosciences Co., Ltd (SHA: 688321), a biopharmaceutical company based in China, has received...

Company Deals

Anhui Anke Biotechnology Receives NMPA Approval for Clinical Trial of HPV-Targeting mRNA Drug AFN0328

Fineline Cube Jul 24, 2024

China-based Anhui Anke Biotechnology (Group) Co., Ltd (SHE: 300009) has announced that it has received...

Company Deals

Novogene and Becton, Dickinson Partner to Advance Single Cell Sequencing Technologies

Fineline Cube Jul 24, 2024

Novogene (SHA: 688315), a genomic services and solutions provider based in Beijing and operating globally,...

Company Deals

Shanghai Desano and Chongqing Kangfude Partner to Establish Peptide Drug Production Base in China

Fineline Cube Jul 24, 2024

Shanghai Desano Biopharmaceutical Co., Ltd, a leading biopharmaceutical company based in China, has entered into...

Company Deals

TowardPi Medical Partners with OCULUS Iberia to Introduce Advanced OCTA Technology to Spain

Fineline Cube Jul 24, 2024

TowardPi (Beijing) Medical Technology Ltd, a Chinese medical technology company specializing in ophthalmic imaging, has...

Company Drug

ViiV Healthcare’s Dovato Shows Non-Inferior Efficacy and Less Weight Gain in Pivotal PASO DOBLE Study

Fineline Cube Jul 24, 2024

ViiV Healthcare, the HIV-focused subsidiary majority-owned by GSK with Pfizer and Shionogi as shareholders, has...

Company

Pfizer Launches SGD 1 Billion API Plant Expansion in Singapore, Creating 250 New Jobs

Fineline Cube Jul 24, 2024

Pfizer Inc., (NYSE: PFE) a leading global pharmaceutical company, has announced the opening of an...

Policy / Regulatory

China’s NHSA Updates DRG/DIP Payment Reform Program with New Exclusion Mechanisms and Timelines

Fineline Cube Jul 23, 2024

The National Healthcare Security Administration (NHSA) in China has issued a notification outlining several updates...

Company Drug

Jiangsu Hansoh’s Loxenatide Matches Dapagliflozin in Diabetes Nephropathy Clinical Trial

Fineline Cube Jul 23, 2024

Jiangsu Hansoh Pharmaceutical Co., Ltd, a leading pharmaceutical company based in China, has published the...

Posts pagination

1 … 267 268 269 … 608

Recent updates

  • China’s NHSA Launches Pre‑Communication Pilot for Reference Drugs, Targeting Category 1 Innovative Drugs
  • RemeGen Licenses RC148 Bispecific to AbbVie for Up to $5.6 Billion in Milestones
  • Broncus Medical Secures NMPA Fast‑Track for BroncTarget COPD System, Targeting 9 Million Refractory Patients in China
  • Boehringer Ingelheim & Jazz Launch Phase I HER2 Breast Cancer Combo with Zongertinib & Zanidatamab
  • Thermo Fisher Scientific Partners with NVIDIA in $280 Million AI Deal to Automate Laboratory Operations
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Policy / Regulatory

China’s NHSA Launches Pre‑Communication Pilot for Reference Drugs, Targeting Category 1 Innovative Drugs

Company Deals

RemeGen Licenses RC148 Bispecific to AbbVie for Up to $5.6 Billion in Milestones

Company Medical Device

Broncus Medical Secures NMPA Fast‑Track for BroncTarget COPD System, Targeting 9 Million Refractory Patients in China

Company Deals

Boehringer Ingelheim & Jazz Launch Phase I HER2 Breast Cancer Combo with Zongertinib & Zanidatamab

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.